FibroGen Company Leadership

FGEN Stock  USD 0.39  0.01  2.50%   
FibroGen's insiders are aggressively buying. The analysis of the overall insider sentiment regarding FibroGen suggests that virtually all insiders are extremely bullish. FibroGen employs about 486 people. The company is managed by 17 executives with a total tenure of roughly 6 years, averaging almost 0.0 years of service per executive, having 28.59 employees per reported executive.

FibroGen's Insider Buying Vs Selling

100

 
Selling
 
Buying

Latest Trades

2024-06-12Deyaa AdibAcquired 22123 @ 1.17View
2024-03-07Thane WettigAcquired 50000 @ 1.91View
Monitoring FibroGen's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroGen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
To learn how to invest in FibroGen Stock, please use our How to Invest in FibroGen guide.

FibroGen Management Team Effectiveness

The company has return on total asset (ROA) of (0.2655) % which means that it has lost $0.2655 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.1579) %, meaning that it created substantial loss on money invested by shareholders. FibroGen's management efficiency ratios could be used to measure how well FibroGen manages its routine affairs as well as how well it operates its assets and liabilities. As of the 26th of November 2024, Return On Tangible Assets is likely to grow to -0.64. In addition to that, Return On Capital Employed is likely to grow to -1.3. At this time, FibroGen's Total Assets are very stable compared to the past year. As of the 26th of November 2024, Non Current Assets Total is likely to grow to about 146.7 M, while Other Assets are likely to drop 0.95.
As of the 26th of November 2024, Common Stock Shares Outstanding is likely to drop to about 78.2 M. In addition to that, Net Loss is likely to grow to about (251.1 M)

FibroGen Workforce Comparison

FibroGen is rated # 4 in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 7,847. FibroGen holds roughly 486 in number of employees claiming about 6% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.97) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.22) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.22.

FibroGen Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific FibroGen insiders, such as employees or executives, is commonly permitted as long as it does not rely on FibroGen's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, FibroGen insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

FibroGen Notable Stakeholders

A FibroGen stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as FibroGen often face trade-offs trying to please all of them. FibroGen's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting FibroGen's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Thane WettigCEO DirectorProfile
Karen BergmanVice President Investor Relations and Corporate CommunicationsProfile
Kirk MBAChief OfficerProfile
Rahul KaushikTechnical DevelopmentProfile
Mr JDChief OfficerProfile
Enrique ConternoCEO DirectorProfile
Barry BerkowitzFounderProfile
Christine ChungSenior OperationsProfile
David DeLuciaVice RelationsProfile
Elizabeth PharmDBiometrics, RegulatoryProfile
Elias KouchakjiDrug DevelProfile
Juan GrahamChief OfficerProfile
Julian SternSecretaryProfile
Deyaa MDSenior OfficerProfile
Tricia StewartChief OfficerProfile
MPH MDEx OfficerProfile
John HunterChief OfficerProfile

About FibroGen Management Performance

The success or failure of an entity such as FibroGen often depends on how effective the management is. FibroGen management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of FibroGen management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the FibroGen management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.67)(0.64)
Return On Capital Employed(1.37)(1.30)
Return On Assets(0.67)(0.64)
Return On Equity 1.39  0.74 

FibroGen Workforce Analysis

Traditionally, organizations such as FibroGen use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare FibroGen within its industry.

FibroGen Manpower Efficiency

Return on FibroGen Manpower

Revenue Per Employee304K
Revenue Per Executive8.7M
Net Loss Per Employee584.8K
Net Loss Per Executive16.7M
Working Capital Per Employee234.3K
Working Capital Per Executive6.7M
When determining whether FibroGen offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of FibroGen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Fibrogen Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Fibrogen Stock:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroGen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
To learn how to invest in FibroGen Stock, please use our How to Invest in FibroGen guide.
You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroGen. If investors know FibroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroGen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.536
Earnings Share
(1.23)
Revenue Per Share
1.758
Quarterly Revenue Growth
0.143
Return On Assets
(0.27)
The market value of FibroGen is measured differently than its book value, which is the value of FibroGen that is recorded on the company's balance sheet. Investors also form their own opinion of FibroGen's value that differs from its market value or its book value, called intrinsic value, which is FibroGen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroGen's market value can be influenced by many factors that don't directly affect FibroGen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between FibroGen's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroGen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroGen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.